Stryker (NYSE:SYK) Shares Down 6.2% – Should You Sell?

Shares of Stryker Corporation (NYSE:SYK) were down 6.2% on Tuesday . The stock traded as low as $286.28 and last traded at $284.2830. Approximately 852,923 shares were traded during mid-day trading, a decline of 64% from the average session volume of 2,347,572 shares. The stock had previously closed at $303.13.

Analyst Ratings Changes

Several research firms have recently weighed in on SYK. Truist Financial increased their price objective on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. dropped their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Citigroup reissued a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. Raymond James Financial set a $370.00 price objective on Stryker in a research note on Friday, July 31st. Finally, Evercore set a $350.00 price target on shares of Stryker in a research note on Monday, July 6th. Eighteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $381.40.

Stryker Stock Down 0.2%

The company has a market capitalization of $105.86 billion, a PE ratio of 28.60, a P/E/G ratio of 1.73 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average of $326.77 and a 200 day moving average of $327.62.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the previous year, the company earned $3.13 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts anticipate that Stryker Corporation will post 15.03 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Insiders Place Their Bets

In related news, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This represents a 11.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Stryker

A number of hedge funds and other institutional investors have recently modified their holdings of SYK. The Manufacturers Life Insurance Company increased its position in Stryker by 8.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock valued at $270,642,000 after buying an additional 65,333 shares in the last quarter. Palogic Value Management L.P. lifted its stake in shares of Stryker by 4.3% in the second quarter. Palogic Value Management L.P. now owns 1,313 shares of the medical technology company’s stock worth $413,000 after buying an additional 54 shares in the last quarter. Tidal Investments LLC increased its holdings in shares of Stryker by 174.2% in the 2nd quarter. Tidal Investments LLC now owns 111,457 shares of the medical technology company’s stock worth $35,091,000 after purchasing an additional 70,805 shares in the last quarter. Van Hulzen Asset Management LLC increased its holdings in Stryker by 3.3% in the 2nd quarter. Van Hulzen Asset Management LLC now owns 15,148 shares of the medical technology company’s stock worth $4,769,000 after buying an additional 481 shares in the last quarter. Finally, National Pension Service lifted its position in Stryker by 2.4% during the second quarter. National Pension Service now owns 721,186 shares of the medical technology company’s stock valued at $227,058,000 after purchasing an additional 16,962 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Company Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.